Evidence map›Paper›PMID 40771123›Full record

ArticleCardiology journal2025

Genetic insights into SGLT2 inhibition and atrial fibrillation: exploring the mediating role of inflammatory proteins.

Chengcheng Yi, Wenyuan Zheng, Junqian Wang, Wenqiang Li, Yiming Zhang, Dan Zhou, Peng Lei, Yongxiang Wang, Ming Bai, Zheng Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chengcheng YiThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Wenyuan ZhengDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, China.
Junqian WangDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, China.
Wenqiang LiThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Yiming ZhangThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Dan ZhouThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Peng LeiThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Yongxiang WangDepartment of Heart Center, The First Hospital of Lanzhou University, Lanzhou, China.
Ming BaiThe First Clinical Medical College, Lanzhou University, Lanzhou, China.
Zheng ZhangThe First Clinical Medical College, Lanzhou University, Lanzhou, China. zhangccu@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to employ Mendelian randomization (MR) analysis to investigate the causal relationship between sodium-glucose cotransporter 2 (SGLT2) inhibition and atrial fibrillation (AF), as well as assess the potential mediating role of inflammatory proteins in this association.

methodsA two-sample MR analysis was conducted using summary-level data from the genome-wide association study (GWAS) were used to evaluate the genetic prediction of SGLT2 inhibition and AF. Additionally, a two-step MR approach was applied to explore the causal mediation effects of inflammatory proteins in the SGLT2-AF pathway.

resultsGenetically predicted SGLT2 inhibition was associated with a significantly lower risk of AF (odds ratio [OR] 0.51; 95% confidence interval [CI]: 0.27-0.97; p = 0.039). Mendelian randomization analysis further identified FGF-23 (OR 0.88; 95% CI: 0.79, 0.98; p = 0.024) and PD-L1 (OR 0.90; 95% CI: 0.82, 0.96; p = 0.023) as significant mediators, accounting for 21.28% and 17.69% of the total effect, respectively.

conclusionsThese findings provide potential protective role of SGLT2 inhibition against AF, mediated by inflammatory proteins. Further mechanistic and clinical investigations are warranted to elucidate the underlying pathways and therapeutic implications.

Indexed as

Atrial FibrillationDiabetes Mellitus, Type 2Fibroblast Growth FactorsInflammation MediatorsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsFibroblast Growth Factor-23Genome-Wide Association StudyHumansMendelian Randomization AnalysisPolymorphism, Single NucleotideRisk FactorsFibroblast Growth Factor-23Fibroblast Growth FactorsInflammation MediatorsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsatrial fibrillationcausal mediationinflammatory proteinsMendelian randomizationSGLT2 inhibition

Identifiers

PMID40771123
PMCPMC12782545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.